At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Juan Ignacio Aróstegui Gorospe, MD, PhD, from the Hospital Clínic de Barcelona, Barcelona, Spain, discusses the efficacy and safety of canakinumab in active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS) and the implications of the results for the future treatment of patients with the condition.
Canakinumab in the treatment active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS)
19th April 2016
Rheumatology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?